

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

64  
1-15-99  
#7

In re Patent Application of:

SCHMIDT

Serial No. 09/295,302

Filed: April 21, 1999


For: AGENT FOR THE  
MANUFACTURE OF BIOLOGICAL  
PARTS ...

)  
) Art Unit:

)  
) Examiner:

)  
) Atty. Docket No. 109572.0101

)  
) KON\pdc



**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

For insuring compliance with the applicant's duty of disclosure under 37 CFR §1.56, the undersigned hereby submits the documents listed on the attached Form PTO-1449 for consideration by the Examiner in charge of the above-identified patent application.

The identification of these documents is for the purpose of meeting applicant's duty of disclosure under 37 CFR §1.56 and is not intended to be an admission that any of these documents constitute prior art as to the invention claimed in the present application.

The Examiner's attention is kindly directed to applicant's parent Application Serial No. 08/350,666 and Patent Nos. 5,830,859 and 5,916,553 and all the documents cited therein, which are listed on the attached PTO Form-1449. Although copies of these documents have been previously provided, we are submitting them again for the convenience of the Examiner.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date or the date of filing a CPA, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.

☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).

☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

☐ c. Attached is our check in the amount of \$240.00 in payment of the fee under 37 CFR §1.17(p). Please credit or debit Deposit Account No. 23-2185 as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.

☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check in the amount of \$130.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please credit or debit Deposit Account No. 23-2185 as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.

☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a

counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).

☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

Respectfully submitted,

By: Karl O. Neidert  
Karl O. Neidert  
Registration No. 39,313  
Attorney for Applicant

Date: July 26, 1999

Customer No. 002779  
BLANK ROME COMISKY & MCCAULEY LLP  
900 - 17th Street, N.W., Suite 1000  
Washington, D.C. 20006  
(202) 463-7700 (phone)  
(202) 463-6915 (facsimile)


Form PTO-1449  
(Rev.9-94)U.S. Department of Commerce  
Patent and Trademark OfficeATTY. DOCKET NO.  
109572.101/PSERIAL NO.  
09/296,302

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT  
Karlheinz SCHMIDTFILING DATE  
April 21, 1999

GROUP



## U. S. PATENT DOCUMENTS

*EXAMINER INITIAL	Document Number	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,472,840	9/25/1984	Jefferies			
	4,294,753	10/1981	Urist			
	5,024,841	08/1991	Chu et al.			
	4,832,686	05/1989	Anderson			
	4,642,120	02/1987	Nevo et al.			
	4,703,108	10/1987	Silver			
	4,950,483	08/1990	Ksander et al.			
	5,916,553	06/1999	Schmidt			
	4,932,973	06/1990	Gendler			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHER INFORMATION (including author, title, date, pertinent pages, etc.)

Heumann et al., Medical Sensation from a Tübingen researcher, May 1989, pp. 1-14 (Germany w/English translation)

Dijke et al., Growth Factors for Wound Healing, Bio/Technology, Volume 7, 1989, pp. 793-798

Laminin, Fibronectin and Other Multiadhesive Matrix Glycoproteins, Chapter 23, Multicellularity: Cell-Cell and Cell-Matrix Interactions, pp. 920-924

Cytokines Stimulate Cell Division, Chapter 19, Cell-to-Cell Signaling: Hormones and Receptors, pp. 756

EXAMINER

DATE CONSIDERED